Kowa ya san sakamakon gwajin rigakafin Pfizer Covid, wanda aka buga a baya a cikin Disamba 2020. An “tabbatar da ƙarshen Covid,” an ayyana aƙalla alama ɗaya tare da ingantaccen gwajin PCR.
Mutane da yawa ba su sani ba, duk da haka, cewa sanannen gwajin yana da wani mahimmin mahimmin ƙarshen-asymptomatic kamuwa da cuta. Ya bayyana a cikin wata doguwar takarda mai suna "Rahoton Cikakkun Nazarin Nazari na Ƙarshe."
Tsakanin kashi ɗaya bisa uku da rabi na cututtukan SARS-CoV-2 sun kasance asymptomatic, kuma an yi imanin watsa asymptomatic ya taka muhimmiyar rawa a cikin cutar.bai yi ba). Wannan shine bayanin hukuma don sanya kulle-kulle (kodayake ba lallai bane na gaskiya). Kuma shi ya sa aka ɗauki kamuwa da cutar asymptomatic a matsayin muhimmin ƙarshen gwaji.
Ana samun sakamakon a wurare da yawa a cikin takaddar Pfizer. Teburin wakilci ɗaya yana nunawa a ƙasa. Muna samun sakamako iri ɗaya a cikin sauran tebur.
Adadin mutanen ya kusan iri ɗaya a cikin makamai biyu, amma lokacin da ke cikin haɗari ya kasance kusan rabin masu karɓar placebo saboda yawancinsu a ƙarshe sun karɓi maganin alurar riga kafi (masu giciye bayan an rufe su). Tunda adadin cututtukan asymptomatic yayi kama (644 da 625), ƙimar ƙimar kusan 0.5 ne, wanda ke nufin tasiri na 50%. Daidaitaccen lissafi a ƙasa:
Ba shi da kyau kamar 90% zuwa 95% tasiri akan kamuwa da cuta - idan kun yi imani da shi mu'ujizai-amma duk da haka, hadarin ya ragu da rabi.
Ya akayi?
Za mu gano nan ba da jimawa ba.
Bayanin ƙasa ya bayyana wanda aka haɗa cikin binciken:
- Sakamakon N-binding antibody mara kyau a ziyara 1
- PCR mara kyau a ziyarar 1 da 2
- PCR mara kyau a kowane lokaci, lokacin da aka auna don alamun alamun da ake zargi
An gano wani lamari ta hanyar gano ƙwayoyin rigakafin N-binding wani lokaci bayan allura ta biyu.
Gwajin jinin N-binding antibody ba a san shi sosai da gwajin PCR ba. Wannan gwajin yana gano ƙwayoyin rigakafi waɗanda ke nufi da furotin nucleocapsid (N). Su ne alamomin kamuwa da cuta a baya.
Don dalilan da ba a fahimta gaba ɗaya ba, allurar rigakafin tana da alaƙa da ƙarancin amsawar anti-N-antibody ga kamuwa da cuta mai zuwa, kuma gwajin ya rasa wasu cututtuka da yawa a cikin alurar riga kafi fiye da waɗanda ba a yi ba. A cikin sharuɗɗan fasaha, ƙwarewar gwajin yana da ƙasa a cikin tsohon. Kungiyoyi uku ne suka ruwaito wannan abin lura.
- Allen et al. an gano cewa an gano ƙwayoyin rigakafin N a cikin kashi 26% na lokuta na kamuwa da cutar bayan allurar rigakafi (6/23), wanda PCR da anti-S (spike) rigakafi suka tabbatar. Mitar ta kasance 82% a cikin duk cututtukan da aka rubuta a baya (663/812). A bayyane yake, gwajin ba a yi shi ba a cikin waɗanda aka yi wa alurar riga kafi, kuma ƙimar gyara shine 3.1 (82/26). Alurar rigakafin Pfizer ce.
- Folman et al. yayi nazarin wannan batu a cikin masu karɓar allurar Moderna. Daga cikin mahalarta tare da PCR-tabbatar da Covid yayin lokacin makantar gwajin, an sami juzu'i zuwa anti-N antibodies a cikin kashi 40% na masu karɓar allurar (21/52) tsakanin 93% na masu karɓar placebo (605/648). Bugu da ƙari, gwajin ba a yi shi ba a cikin allurar rigakafi, kuma ma'aunin gyara shine 2.3 (93/40).
- Dhakal et al. ya tabbatar da sakamakon binciken a cikin jerin jadawalai, yana nuna raguwar martanin rigakafin anti-N na tsawon lokaci a cikin kamuwa da cutar bayan allurar. Ba su bayar da kashi iri ɗaya ba.
Ingantacciyar kwatancen hannaye biyu na gwajin Pfizer yana buƙatar gyara adadin cututtukan asymptomatic a hannun rigakafin don ƙididdige su ta hanyar gwajin. Ya kasance da yawa fiye da lokuta 644. Dangane da binciken da na kawo, ya kamata mu ninka adadin da 2 zuwa 3.
Idan muka ninka lambar (matsalar gyara na 2), tasirin gaske ya kasance kusan sifili. Idan muka ninka ta 2.5, muna shigar da kewayon tasiri mara kyau.
Alurar rigakafin Pfizer ba ta da amfani ko mafi muni akan kamuwa da cutar asymptomatic.
Binciken da na yi na PubMed bai sami wani labari kan rigakafin mRNA da kamuwa da cutar asymptomatic ba a cikin gwajin Pfizer. Ina mamakin dalili. Shin sun yi jinkirin bayyana tasirin 50%, ko sun damu cewa wani matsayi kamar nawa zai iya nunawa a matsayin wasiƙar zuwa ga edita? Idan na ƙarshe, ba sa buƙatar damuwa—haka a 2021 ko kuma daga baya.
-
Dokta Eyal Shahar farfesa ne a fannin kiwon lafiyar jama'a a fannin cututtukan cututtuka da kididdiga. Binciken nasa yana mayar da hankali ne akan ilimin cututtuka da kuma hanyoyin. A cikin 'yan shekarun nan, Dr. Shahar ya ba da gudummawa sosai ga hanyoyin bincike, musamman a fannin zane-zane da kuma son zuciya.
Duba dukkan posts
